Therapeutic trem-1 peptides

Patent metadata

Field	Value
Publication number	US-2016193288-A1
Application number	US-201514968479-A
Country	US
Kind code	A1
Filing date	Dec 14, 2015
Priority date	Nov 29, 2004
Publication date	Jul 7, 2016
Grant date	—

Abstract

A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.

First claim

1 .- 40 . (canceled)

41 . An isolated peptide or a derivative thereof, which is capable of acting as antagonist of the TREM-1 protein as defined by SEQ ID NO.2, comprising SEQ ID NO. 22 or at least 3 amino acids from SEQ ID NO. 23, wherein:
(a) the polypeptide consists of:
(i) a contiguous sequence of 5 to 29 amino acids from SEQ ID NO: 2; or
(ii) a contiguous sequence of 5 to 29 amino acids from SEQ ID NO: 2 in which one amino acid is substituted conservatively with another amino acid;
or (b) the polypeptide consists of an amino acid sequence having at least 80% sequence identity to SEQ ID NOS: 3, 4, 6 or 7; wherein the derivatives of the polypeptides of (a) or (b) are modified by glycosylation, acetylation, pegylation, phosphorylation, amidation, or derivatization by protecting or blocking groups.

42 . The isolated peptide or derivative thereof according to claim 41 which consists of:
(a) a contiguous sequence of 5 to 29 amino acids from SEQ ID NO: 2; or
(b) a contiguous sequence of 5 to 29 amino acids from SEQ ID NO: 2 in which one amino acid is substituted conservatively with another amino acid;

and wherein the derivatives of the polypeptides of (a) or (b) are modified by glycosylation, acetylation, pegylation, phosphorylation, amidation, or derivatization by protecting or blocking groups.

43 . The isolated peptide or derivative thereof according to claim 41 wherein the polypeptide consists of an amino acid sequence having at least 80% sequence identity to SEQ ID NOS: 3, 4, 6 or 7;
and wherein the derivatives of the polypeptide are modified by glycosylation, acetylation, pegylation, phosphorylation, amidation, or derivatization by protecting or blocking groups.

44 . The isolated peptide or derivative thereof according to claim 41 , wherein said polypeptide consists of a contiguous sequence of 15 to 29 amino acids from SEQ ID NO.2.

45 . The isolated peptide or derivative thereof according to claim 41 which comprises at least 3 amino acids from SEQ ID NO. 23 wherein the at least 3 amino acids from SEQ ID NO. 23 are selected from the group consisting of HPP, HPPN (SEQ ID NO 25), and HPPND (SEQ ID NO 23).

46 . A polypeptide that is a fusion protein comprising the isolated peptide or derivative thereof according to claim 41 and a heterologous polypeptide.

47 . A polypeptide according to claim 46 wherein the heterologous polypeptide is selected from the group consisting of: a sequence derived from an immunoglobulin, a non-classical alternative protein scaffold a heterologous signal sequence fused to the N-terminus of the peptide according to claim 41 or derivative thereof, and a tag sequence.

48 . A pharmaceutical composition comprising a peptide or derivative thereof according to claim 41 and a pharmaceutically acceptable carrier.

Assignees

• Bristol Myers Squibb Co
• Univ Lorraine

Inventors

• Faure Gilbert
• Gibot Sebastien
• Panina Paola
• Passini Nadia

Classifications

• C07K14/70503 Primary

  Immunoglobulin superfamily · CPC title

• A61K38/177 Primary

  Receptors; Cell surface antigens; Cell surface determinants · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2319/70

  containing domain for protein-protein interaction · CPC title